| Item |
Information |
|
Drug Groups
|
illicit; approved |
|
Description
|
A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound. Dronabinol is a synthetic form of delta-9-THC. [PubChem] |
| Indication |
For the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments |
| Pharmacology |
Marinol may has complex effects on the central nervous system (CNS), including cannabinoid receptors. Dronabinol may inhibit endorphins in the emetic center, suppress prostaglandin synthesis, and/or inhibit medullary activity through an unspecified cortical action. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Biotransformation |
Hepatic |
| Absorption |
90 - 95% |
| Half Life |
Alpha phase: approximately 4 hours; Beta phase: 25-36 hours |
| Protein Binding |
97% |
| Elimination |
Dronabinol and its biotransformation products are excreted in both feces and urine. |
| Distribution |
* 10 L/kg |
| Clearance |
* 0.2 L/kg-hr |
| External Links |
|